Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The EGFR inhibitor cetuximab is approved for the treatment of colorectal cancer. However, both innate and acquired resistance mechanisms, including compensatory feedback loops, limit its efficacy. Nevertheless, the emergence of these feedback loops has remained largely unexplored to date. Here, we showed feedback upregulation of HER3 and induction of HER3 phosphorylation after cetuximab treatment in colon cancer cells. We also showed that this upregulation occurs, at least partly, through AKT inhibition. Together with this, we observed increased HER2:HER3 dimerization upon cetuximab treatment. Interestingly, lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, blocked the increase of cetuximab-induced HER3 phosphorylation. Additionally, we showed that upon HER3 knockdown, cetuximab combined with lapatinib was able to decrease cell viability compared to HER3 expressing cells. These results suggest the existence of a cetuximab-induced feedback HER3 activation that could potentially result in reduced cetuximab efficacy in colorectal cancer patients. Taken together, we provide evidence of the limited effectiveness of cetuximab monotherapy compared to rational combinations.

Original publication

DOI

10.18632/oncotarget.13834

Type

Journal article

Journal

Oncotarget

Publication Date

17/01/2017

Volume

8

Pages

4277 - 4288

Keywords

HER3, cetuximab resistance, colorectal cancer, dimerization, feedback loop, Cell Line, Tumor, Cell Proliferation, Cell Survival, Cetuximab, Colonic Neoplasms, Drug Resistance, Neoplasm, ErbB Receptors, Feedback, Physiological, Humans, Lapatinib, Phosphorylation, Protein Kinase Inhibitors, Protein Multimerization, Quinazolines, Receptor, ErbB-2, Receptor, ErbB-3, Up-Regulation